Research News
View articles by month and year
-
Taxol Plus Tykerb Better Than Taxol Alone to Treat HER2-Positive, Metastatic Disease
The combination of Taxol and Tykerb offers more benefits in treating newly diagnosed metastatic, HER2-positive breast cancer than Taxol alone.
-
Tykerb and Xeloda Seem to Shrink HER2-Positive Breast Cancer That’s Spread to Brain
A very small, very early study suggests the combination of Tykerb and Xeloda shrinks HER2-positive breast cancer lesions in the brain without radiation.
-
T-DM1 Lengthens Survival in Women Diagnosed with HER2-Positive Advanced-Stage Disease
Women diagnosed with HER2-positive advanced-stage breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen.
-
T-DM1 Improves Survival in Women with HER2-Positive Metastatic Breast Cancer
Women diagnosed with HER2-positive metastatic breast cancer lived longer when they got the experimental medicine T-DM1 compared to women who got a different targeted therapy regimen.
-
Studies Evaluate Treatments Before Surgery for HER2-Positive Disease
Research suggests that using both Herceptin and Tykerb with Taxol before surgery to treat early-stage or locally advanced HER2-positive breast cancer is better than either alone with Taxol; if only one is given before surgery, Herceptin offers more benefits than Tykerb.
-
Tykerb Alone Doesn’t Work as Well as Herceptin Alone to Treat Early-Stage, HER2-Positive Disease
Early results from the ALTTO study show that Tykerb doesn't work as well as Herceptin when given alone after surgery to treat early-stage, HER2-positive breast cancer.
-
Adding Tykerb to Herceptin and Chemo Improves Survival in Metastatic, HER2-Positive Disease
Research suggests that treating women diagnosed with metastatic, HER2-positive breast cancer with Tykerb and Herceptin and chemotherapy improves survival compared to only Herceptin and chemotherapy.
-
Tykerb and Xeloda Can Help Treat Breast Cancer That’s Spread to the Brain
A small, early study found that treating women diagnosed with metastatic, HER2-positive breast cancer that has spread to the brain with a combination of Tykerb and Xeloda can shrink the cancer in some women.
-
Herceptin More Effective Than Tykerb When Given Before Surgery
Research suggests that Herceptin is more effective than Tykerb in a neoadjuvant regimen for early-stage or locally-advanced HER2-positive breast cancer.
-
Herceptin and Tykerb Added to Chemo Before Surgery More Effective Than Adding Only One to Treat Early-Stage, HER2-Positive Disease
Giving both Herceptin and Tykerb with paclitaxel before surgery for HER2-positive breast cancer offered more benefits than Herceptin or Tykerb alone with paclitaxel new research shows.
